BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started

Медицинский совет

K. K. Laktionov¹  I. A. Dzhanyan¹  L. A. Kostyakova¹  E. R. Virshke¹  M. U. Pitkevich¹  V. V. Breder¹ 

[1] N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia;

关键词: hepatocellular carcinoma;    hcc;    transarterial chemoembolization (tace);    sorafenib;    regorafenib;    bclc;   

DOI  :  10.21518/2079-701X-2018-10-27-32

来源: DOAJ

【 摘 要 】

Choice of the optimal therapy for BCLC-B hepatocellular carcinoma (HCC) is a significant clinical problem. Transarterial chemoembolisation (TACE) is considered to be the method of choice as this approach is reported to produce a direct effect and to have a significant survival rate. However, TACE is not always applicable and produce a survival benefit due to the clinical heterogeneity of BCLC-B HCC. The article includes different approaches for BCLC-B HCC patients, TACE prediction and refractory criteria as well as the results obtained. The necessity of timely sorafenib systemic therapy in BCLC-B and in advanced HCC after TACE is discussed. Practical application of regorafenib as the second line in HCC systemic treatment is discussed.

【 授权许可】

Unknown